IL93456A - D2 Aphimer of A1- hydroxyvitamin and pharmaceutical preparations containing it - Google Patents

D2 Aphimer of A1- hydroxyvitamin and pharmaceutical preparations containing it

Info

Publication number: IL93456A
Authority: IL; Israel
Prior art keywords: vitamin; hydroxy; compound; epi; hydroxyvitamin
Prior art date: 1989-03-09

Application number

IL9345690A

Other languages

English (en)

Hebrew (he)

Other versions

IL93456A0 (en

Original Assignee

Wisconsin Alumni Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-09

Filing date

1990-02-20

Publication date

1994-02-27

1990-02-20 Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found

1990-11-29 Publication of IL93456A0 publication Critical patent/IL93456A0/xx

1994-02-27 Publication of IL93456A publication Critical patent/IL93456A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title description 2
HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 35
125000002252 acyl group Chemical group 0.000 claims description 6
125000005103 alkyl silyl group Chemical group 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 3
239000000825 pharmaceutical preparation Substances 0.000 claims 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
150000002431 hydrogen Chemical class 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000011575 calcium Substances 0.000 abstract description 20
230000000694 effects Effects 0.000 abstract description 20
229910052791 calcium Inorganic materials 0.000 abstract description 19
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 17
210000000988 bone and bone Anatomy 0.000 abstract description 15
230000004069 differentiation Effects 0.000 abstract description 13
230000000968 intestinal effect Effects 0.000 abstract description 7
230000004936 stimulating effect Effects 0.000 abstract description 5
-1 vitamin D2 compound Chemical class 0.000 abstract description 5
201000010099 disease Diseases 0.000 abstract description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
229960002061 ergocalciferol Drugs 0.000 abstract description 3
239000011653 vitamin D2 Substances 0.000 abstract description 3
230000001939 inductive effect Effects 0.000 abstract description 2
230000027425 release of sequestered calcium ion into cytosol Effects 0.000 abstract description 2
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 abstract 1
235000001892 vitamin D2 Nutrition 0.000 abstract 1
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
229940088594 vitamin Drugs 0.000 description 23
239000011782 vitamin Substances 0.000 description 23
239000000203 mixture Substances 0.000 description 13
239000011710 vitamin D Substances 0.000 description 13
229940046008 vitamin d Drugs 0.000 description 13
150000003462 sulfoxides Chemical class 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000000243 solution Substances 0.000 description 10
229930003316 Vitamin D Natural products 0.000 description 9
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 9
230000032258 transport Effects 0.000 description 9
235000019166 vitamin D Nutrition 0.000 description 9
150000003710 vitamin D derivatives Chemical class 0.000 description 9
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
229940093499 ethyl acetate Drugs 0.000 description 8
235000019439 ethyl acetate Nutrition 0.000 description 8
238000000034 method Methods 0.000 description 8
238000003556 assay Methods 0.000 description 7
229930003231 vitamin Natural products 0.000 description 7
235000013343 vitamin Nutrition 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical class [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
150000003722 vitamin derivatives Chemical class 0.000 description 6
MZWRKRWZTKMJOZ-VXKWHMMOSA-N 2-[(2s)-2,3-dimethylbutyl]-4-[3-[(2s)-2,3-dimethylbutyl]-4-methylphenyl]sulfonyl-1-methylbenzene Chemical compound C1=C(C)C(C[C@H](C)C(C)C)=CC(S(=O)(=O)C=2C=C(C[C@H](C)C(C)C)C(C)=CC=2)=C1 MZWRKRWZTKMJOZ-VXKWHMMOSA-N 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
229910052786 argon Inorganic materials 0.000 description 4
150000002440 hydroxy compounds Chemical class 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
150000003457 sulfones Chemical class 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
MZWRKRWZTKMJOZ-FGZHOGPDSA-N 2-[(2r)-2,3-dimethylbutyl]-4-[3-[(2r)-2,3-dimethylbutyl]-4-methylphenyl]sulfonyl-1-methylbenzene Chemical compound C1=C(C)C(C[C@@H](C)C(C)C)=CC(S(=O)(=O)C=2C=C(C[C@@H](C)C(C)C)C(C)=CC=2)=C1 MZWRKRWZTKMJOZ-FGZHOGPDSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010057249 Phagocytosis Diseases 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000024245 cell differentiation Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
239000011707 mineral Substances 0.000 description 3
235000010755 mineral Nutrition 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000008782 phagocytosis Effects 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000018678 bone mineralization Effects 0.000 description 2
239000012267 brine Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
230000001483 mobilizing effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
NQICGNSARVCSGJ-JTTVCCKGSA-N (5-methyl-2-propan-2-ylcyclohexyl) 4-methylbenzenesulfinate Chemical compound CC(C)C1CCC(C)CC1O[S@@](=O)C1=CC=C(C)C=C1 NQICGNSARVCSGJ-JTTVCCKGSA-N 0.000 description 1
YKZYRVIFGPGJJI-UHFFFAOYSA-N 1-[1-[2,3-dimethyl-1-(4-methylphenyl)butyl]sulfinyl-2,3-dimethylbutyl]-4-methylbenzene Chemical class C=1C=C(C)C=CC=1C(C(C)C(C)C)S(=O)C(C(C)C(C)C)C1=CC=C(C)C=C1 YKZYRVIFGPGJJI-UHFFFAOYSA-N 0.000 description 1
MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
SXSWMAUXEHKFGX-UHFFFAOYSA-N 2,3-dimethylbutan-1-ol Chemical compound CC(C)C(C)CO SXSWMAUXEHKFGX-UHFFFAOYSA-N 0.000 description 1
MPHUAKIJAGYUEQ-VXKWHMMOSA-N 2-[(2s)-2,3-dimethylbutyl]-4-[3-[(2s)-2,3-dimethylbutyl]-4-methylphenyl]sulfinyl-1-methylbenzene Chemical compound C1=C(C)C(C[C@H](C)C(C)C)=CC(S(=O)C=2C=C(C[C@H](C)C(C)C)C(C)=CC=2)=C1 MPHUAKIJAGYUEQ-VXKWHMMOSA-N 0.000 description 1
ULQQGOGMQRGFFR-UHFFFAOYSA-N 2-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC=C1Cl ULQQGOGMQRGFFR-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
229910000497 Amalgam Inorganic materials 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
238000003747 Grignard reaction Methods 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010031240 Osteodystrophy Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000009471 action Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
230000000125 calcaemic effect Effects 0.000 description 1
230000002308 calcification Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
239000010410 layer Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
150000004807 phenyl sulfones Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
210000004765 promyelocyte Anatomy 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
229910001023 sodium amalgam Inorganic materials 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
150000003431 steroids Chemical group 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000004704 ultra performance liquid chromatography Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Nutrition Science (AREA)
Endocrinology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL9345690A 1989-03-09 1990-02-20 D2 Aphimer of A1- hydroxyvitamin and pharmaceutical preparations containing it IL93456A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/321,254 US4973584A (en)	1989-03-09	1989-03-09	Novel 1α-hydroxyvitamin D2 epimer and derivatives

Publications (2)

Publication Number	Publication Date
IL93456A0 IL93456A0 (en)	1990-11-29
IL93456A true IL93456A (en)	1994-02-27

Family

ID=23249837

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9345690A IL93456A (en)	1989-03-09	1990-02-20	D2 Aphimer of A1- hydroxyvitamin and pharmaceutical preparations containing it

Country Status (15)

Country	Link
US (1)	US4973584A (de)
EP (1)	EP0386793B1 (de)
JP (1)	JPH0737443B2 (de)
KR (1)	KR950005776B1 (de)
AT (1)	ATE90342T1 (de)
AU (1)	AU631618B2 (de)
CA (1)	CA1335105C (de)
DE (1)	DE69001839T2 (de)
DK (1)	DK0386793T3 (de)
ES (1)	ES2055193T3 (de)
HU (1)	HU207040B (de)
IL (1)	IL93456A (de)
NZ (1)	NZ232735A (de)
RU (1)	RU2065851C1 (de)
WO (1)	WO1990010619A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5030772A (en) *	1990-02-14	1991-07-09	Deluca Hector F	Process for preparing vitamin D2 compounds and the corresponding 1 α-hydroxylated derivatives
US5260290A (en) *	1990-02-14	1993-11-09	Wisconsin Alumni Research Foundation	Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
US5756783A (en) *	1990-09-21	1998-05-26	Bone Care International, Inc.	1α-Hydroxy-24-EPI-vitamin D4
US6251883B1 (en)	1991-01-08	2001-06-26	Bone Care International, Inc.	Methods for preparation and use of 1α,24(S)-dihydroxy vitamin D2
US6538037B2 (en)	1991-01-08	2003-03-25	Bone Care International, Inc.	Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US20040009958A1 (en) *	1991-01-08	2004-01-15	Bone Care International, Inc.	Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5789397A (en) *	1991-01-08	1998-08-04	Bone Care International, Inc.	Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2
US5182396A (en) *	1991-03-29	1993-01-26	Nisshin Flour Milling Co., Ltd.	1-hydroxyvitamin d derivatives
ATE144250T1 (de) *	1991-12-26	1996-11-15	Wisconsin Alumni Res Found	26,27-dimethylen-1-alpha, 25-dihydroxyvitamin-d2 und 26,27-dihydroxyvitamin-d2 und verfahren zu ihrer herstellung
CA2129120A1 (en) *	1992-01-29	1993-08-05	Bone Care International, Inc.	1.alpha.-hydroxy-24-epi-vitamin d4
US5194431A (en) *	1992-07-08	1993-03-16	Wisconsin Alumni Research Foundation	24-cyclopropane vitamin D derivatives
EP0614456B1 (de) *	1992-08-28	1999-06-09	Bone Care International, Inc.	1alpha,24(s)-dihydroxy vitamin d2, seine synthese und verwendung
TW267161B (de) *	1992-11-20	1996-01-01	Hoffmann La Roche
JPH0753384A (ja) *	1993-07-13	1995-02-28	Wisconsin Alumni Res Found	２４−エピ−１α−ヒドロキシビタミンＤ２を含んでなる骨粗鬆症治療剤
US5565589A (en) *	1993-11-03	1996-10-15	Wisconsin Alumni Research Foundation	17-formyl-5,6-trans-vitamin D compounds
US5373004A (en) *	1993-11-24	1994-12-13	Wisconsin Alumni Research Foundation	26,28-methylene-1α, 25-dihydroxyvitamin D2 compounds
US5661140A (en) *	1994-11-21	1997-08-26	Wisconsin Alumni Research Foundation	18-nor-vitamin D compounds
US5716946A (en) *	1996-02-13	1998-02-10	Wisconsin Alumni Research Foundation	Multiple sclerosis treatment
WO2000028982A2 (en)	1998-11-19	2000-05-25	The Board Of Trustees For The University Of Arkansas	Increasing bone strength with selected bisphosphonates
EP1745787B1 (de) *	1999-04-01	2016-11-09	Johns Hopkins University	NICHT-CALCEMISCHE, TRANSKRIPTIONELL-AKTIVE, SCHWEFELHALTIGE ANALOGA VON 1-alpha, 25-DIHYDROXYVITAMIN D3 MIT ANTIPROLIFERATIVER WIRKUNG
US6479474B2 (en) *	1999-07-08	2002-11-12	Wisconsin Alumni Research Foundation	Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
WO2003018545A1 (en) *	2001-08-22	2003-03-06	Johns Hopkins University	24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3?
US7101865B2 (en)	2002-06-13	2006-09-05	Cytochroma Inc.	24-sulfoximine vitamin D3 compounds
US8106035B2 (en)	2002-12-18	2012-01-31	Cytochroma Inc.	25-SO2-substituted analogs of 1μ,25-dihydroxyvitamin D3
AU2004266706B2 (en) *	2003-08-20	2009-07-30	Wisconsin Alumni Research Foundation	2-methylene-19-nor-vitamin D2 compounds
CA2981549A1 (en)	2009-01-27	2010-08-05	Berg Llc	Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN106265695B (zh)	2009-08-14	2021-05-07	博格有限责任公司	用于治疗脱发的维生素d3及其类似物
CN112156097A (zh)	2013-05-29	2021-01-01	博格有限责任公司	使用维生素d预防或减轻化疗诱发的脱发

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3907843A (en) *	1974-06-14	1975-09-23	Wisconsin Alumni Res Found	1{60 -Hydroxyergocalciferol and processes for preparing same
US3880894A (en) *	1974-05-24	1975-04-29	Wisconsin Alumni Res Found	1,25-Dihydroxyergocalciferol
CH665834A5 (de) *	1983-05-09	1988-06-15	Wisconsin Alumni Res Found	Verfahren zur herstellung von 1alpha,25-dihydroxyliertem vitamin d(2) und verwandten verbindungen.
US4769181A (en) *	1983-11-07	1988-09-06	Wisconsin Alumni Research Foundation	1,25-dihydroxyvitamin D2 compounds
US4588528A (en) *	1984-05-31	1986-05-13	Wisconsin Alumni Research Foundation	1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same
US4612308A (en) *	1984-11-29	1986-09-16	Hoffmann-La Roche Inc.	25,26-Dehydro-1α,23(S,R)-dihydroxycholecalciferol and its epimers
US4717721A (en) *	1985-05-30	1988-01-05	Howard W. Bremer	Sidechain homo-vitamin D compounds with preferential anti-cancer activity

1989
- 1989-03-09 US US07/321,254 patent/US4973584A/en not_active Expired - Lifetime
- 1989-09-22 CA CA000612518A patent/CA1335105C/en not_active Expired - Fee Related
1990
- 1990-02-16 KR KR1019900702409A patent/KR950005776B1/ko not_active Expired - Fee Related
- 1990-02-16 WO PCT/US1990/000952 patent/WO1990010619A1/en not_active Ceased
- 1990-02-16 AU AU51925/90A patent/AU631618B2/en not_active Ceased
- 1990-02-16 JP JP2504397A patent/JPH0737443B2/ja not_active Expired - Lifetime
- 1990-02-16 HU HU8822A patent/HU207040B/hu not_active IP Right Cessation
- 1990-02-16 RU SU904831932A patent/RU2065851C1/ru active
- 1990-02-20 IL IL9345690A patent/IL93456A/en not_active IP Right Cessation
- 1990-02-28 NZ NZ232735A patent/NZ232735A/en unknown
- 1990-03-09 EP EP90104564A patent/EP0386793B1/de not_active Expired - Lifetime
- 1990-03-09 DE DE9090104564T patent/DE69001839T2/de not_active Expired - Fee Related
- 1990-03-09 AT AT90104564T patent/ATE90342T1/de not_active IP Right Cessation
- 1990-03-09 ES ES90104564T patent/ES2055193T3/es not_active Expired - Lifetime
- 1990-03-09 DK DK90104564.1T patent/DK0386793T3/da active

Also Published As

Publication number	Publication date
DE69001839D1 (de)	1993-07-15
HU902288D0 (en)	1991-07-29
EP0386793B1 (de)	1993-06-09
JPH03504508A (ja)	1991-10-03
JPH0737443B2 (ja)	1995-04-26
WO1990010619A1 (en)	1990-09-20
KR920700201A (ko)	1992-02-19
ATE90342T1 (de)	1993-06-15
CA1335105C (en)	1995-04-04
EP0386793A1 (de)	1990-09-12
AU5192590A (en)	1990-10-09
US4973584A (en)	1990-11-27
ES2055193T3 (es)	1994-08-16
RU2065851C1 (ru)	1996-08-27
KR950005776B1 (ko)	1995-05-30
DK0386793T3 (da)	1993-08-02
HU207040B (en)	1993-03-01
DE69001839T2 (de)	1993-09-16
AU631618B2 (en)	1992-12-03
IL93456A0 (en)	1990-11-29
NZ232735A (en)	1992-07-28

Legal Events

Date	Code	Title
1996-05-14	KB	Patent renewed
2000-08-13	KB	Patent renewed
2004-11-10	RH1	Patent not in force

Publication	Publication Date	Title
AU631618B2 (en)	1992-12-03	Novel 1alpha-hydroxyvitamin d2 epimer and derivatives
US5260290A (en)	1993-11-09	Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives
WO1990000541A1 (en)	1990-01-25	Novel cyclopentano-vitamin d analogs
SK45895A3 (en)	1995-08-09	25-carboxylic acid derivatives in the vitamin d series, method of producing them, intermediate products for this method, pharmaceutical preparation containing these derivatives and their use in the manufacture of medicines
CZ403197A3 (cs)	1998-07-15	Deriváty vitaminu D se substituenty v poloze C-25, způsob jejich výroby, meziprodukty pro tento způsob, jakož i jejich použití pro výrobu léčiv
JP2731839B2 (ja)	1998-03-25	同族化されたビタミンＤ▲下２▼化合物および対応する１α―ヒドロキシル化誘導体
US5250523A (en)	1993-10-05	Side chain unsaturated 1α-hydroxyvitanim D homologs
JPH0480022B2 (de)	1992-12-17
RU2057117C1 (ru)	1996-03-27	ГОМОЛОГИ 1α - ГИДРОКСИВИТАМИНА D3 С НЕНАСЫЩЕННОЙ БОКОВОЙ ЦЕПЬЮ, КОМПОЗИЦИЯ, СПОСОБСТВУЮЩАЯ СТИМУЛЯЦИИ И УСИЛЕНИЮ ДИФФЕРЕНЦИАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ЛЕЙКЕМИИ ЧЕЛОВЕКА, СПОСОБ СТИМУЛЯЦИИ И УСИЛЕНИЯ ДИФФЕРЕНЦИАЦИИ ЗЛОКАЧЕСТВЕННЫХ КЛЕТОК ЛЕЙКЕМИИ ЧЕЛОВЕКА
JP4988551B2 (ja)	2012-08-01	２−アルキリデン１８，１９−ジノル−ビタミンｄ化合物
FI100598B (fi)	1998-01-15	Menetelmä uusien terapeuttisesti käyttökelpoisten sivuketjuhomologiste n vitamiini-D-johdannaisten valmistamiseksi
CA2062520C (en)	1998-08-11	Synthesis of 1-alpha-hydroxy-secosterol compounds
EP0624573B1 (de)	1997-10-15	Jodvitamin-D-Verbindungen und Verfahren zu ihrer Herstellung
US5446174A (en)	1995-08-29	1-β7,8-trihydroxy vitamin D2, 1β7,8-trihydroxy vitamin D.sub.
US5089647A (en)	1992-02-18	Method for preparing intermediates for the synthesis of steroid side chains in optically active form
IL89499A (en)	1996-10-31	Manufacture of 1beta 7 8 -trihydroxy vitamin d2 and d3 derivatives